One-Year Results of the Use of Absorb Bioresorbable Vascular Scaffold in Patients with Different Forms of Coronary Artery Disease as Compared to a Drug-Eluting Stent

Abstract

The aim of this study was to evaluate the immediate and long-term (12 months) clinical and angiographic efficacy of myocardial revascularization using Absorb GT1 Bioresorbable Vascular Scaffold (BVS) in comparison to second-generation drug-eluting stent (DES) in patients with various forms of coronary artery disease (CAD). Material and Methods: The study included 152 patients with CAD. There were 131 men and 32 women with an average age of 54.6±10.4 years. Patients' data were evaluated retrospectively from the medical records. Results: • Implantation of BVS in patients with different forms of CAD did not cause any angiographic or clinical complications, either at the hospital or at 12-month observation stages, and the results were comparable to those of the DES group. • The technique of implanting BVS and the reception of dual antiplatelet therapy are the key factors for achieving positive results in real clinical practice. • The use of BVS-frameworks contributes to improving clinical, functional and laboratory indicators, while the observed positive dynamics are comparable to similar data of the DES group. • Regardless of the type of implanted stents, the survival rate among CAD patients within 12 months after stenting was 100%, while none of the respondents during this time developed acute MI or recurrence of angina attacks.

Keywords

• Absorb bioresorbable vascular scaffold
• drug-eluting stent
• coronary artery disease